NL-OMON34605
Completed
Phase 3
D-cycloserine (DCS) enhancement of exposure therapy in panic disorder with agoraphobia: a randomized controlled trial. - D-cycloserine enhancement of exposure therapy
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- panic disorder with agoraphobia/panic attacks with phobia in open spaces
- Sponsor
- niversiteit Utrecht
- Enrollment
- 60
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- adult patients (between 18 and 55 years old) with panic disorder with agoraphobia (PD\+AGO), according to DSM IV diagnoses as established using a standardized interview.
- •\- patients are referred to the outpatient clinic of one of the three participating centers.
Exclusion Criteria
- •Patients with
- •\- comorbid psychiatric disorder (severe major depressive disorder, bipolar disorder, psychosis, dependence and/or abuse of alcohol/drugs during the past three months)
- •\- mental deficiency
- •\- inability to adequately read or speak Dutch
- •\- (a history of) neurological disease (i.e. neurovascular disease, movement disorders, seizures, dementia), renal or liver abnormalities
- •\- a history of allergies, adverse reactions or rash on medication
- •\- currently taking benzodiazepines during the day since benzodiazepines might hamper therapy effect (use of stable dosage of evening medication is allowed)
- •\- pregnancy or breastfeeding at the time of the study (in case of possible pregnancy, a pregnancy test will be offered)
- •\- use of isoniazide
- •\- use of variable dosages of antidepressiva (SSRI's or TCA's). (The use of a fixed dosage is NOT an exclusion criterium, but will be registered)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
D-cycloserine (DCS) enhancement of exposure therapy in panic disorder with agoraphobia: a randomized controlled trial. - D-cycloserine enhancement of exposure therapypanic disorder with agoraphobiaMedDRA version: 12.1Level: LLTClassification code 10052794Term: Panic disorder with agoraphobiaEUCTR2010-021198-35-NLniversity Utrecht
Withdrawn
Phase 3
D-cycloserine (DCS) enhancement of exposure and response prevention (ERP) therapy in panic disorder with agoraphobia: a randomized controlled trial.Panic disorder with agorphobia /panic attack with fobia open spaces10002861NL-OMON34949niversiteit Utrecht72
Active, not recruiting
Not Applicable
D-cycloserine augmented exposure therapy in patients with agoraphobiaEUCTR2011-001398-19-DECharité Universitätsmedizin Berlin
Active, not recruiting
Phase 1
D-CYCLOSERINE ENHANCEMENT OF EXPOSURE TREATMENT OF DENTALLY FEARFUL AND AVOIDANT CHILDREN. A PILOT STUDYAvoidance of dental care because of dental anxiety often result in reduced dental health and need for sedation or treatment in general anesthesia. Treatment of dental anxiety is time consuming and not given priority. D-cycloserine has shown to increase the effectiveness of the anxiety/ phobia treatment among adults, but needs to be tested among younger age groups. A medication that will enhance the effect of the anxiety treatment would be of great advantage for the fearful young patient.EUCTR2010-019712-20-NOniversity of Oslo, Institute of Clinical Dentistry
Not yet recruiting
Not Applicable
DCS as an enhancer of ERP in panic disorder and OCD.Panic disorder with agoraphobia, and obsessive-compulsive disorder are studied using DCS either before or afer exposure with response prevention sessions.NL-OMON25942trecht University, department of clinical psychology120